OOKP surgery can restore useful and lasting vision in patients suffering from end-stage ocular surface disease, for whom conventional corneal surgery is not possible. The main problems seen in this study were laminar resorption, particularly in allografts, and glaucoma.

Purpose To evaluate the safety and efficacy of surgical implantation of prosthetic iris devices in patients with iris deficiency. Methods Nine patients with traumatic iris defects, congenital aniridia or iris coloboma, and surgical or optical iridectomies were included in a noncomparative case series. Cataract surgery with intraocular lens and prosthetic iris implantation was performed in 10 eyes. The visual acuity, subjective degree of glare disability, postoperative anatomic results, and intraoperative and postoperative complications were evaluated. Results The mean follow-up was 17.75 months (range 4-48 months). Best-corrected visual acuity improved in nine of 10 eyes (90%) and remained unchanged in one eye. Glare subjectively improved in four of five eyes (80%) of patients complaining of glare preoperatively. All eyes achieved the desired anatomic result. Intraoperative complications included one anterior capsular tear. Postoperative complications included a short period of mild postoperative anterior uveitis in four eyes. Secondary glaucoma was absent. Conclusion In patients with iris deficiency, implantation of prosthetic iris device, and intraocular lens implant following cataract surgery appears to be safe and effective in reducing glare disability and improving visual outcomes.

No abstract

No abstract

Purpose To evaluate the intraocular pressure (IOP)‐lowering efficacy of a preservative‐free formulation of fixed‐combination bimatoprost/timolol (FCBT PF) in treatment (tx)‐naïve vs previously treated patients. Methods A double‐masked, randomized, parallel‐group study compared FCBT PF with preserved FCBT (Ganfort) in 561 patients diagnosed with glaucoma or ocular hypertension who were tx naïve or had inadequate IOP lowering with previous tx. IOP was measured at 0, 2, and 8 hours at baseline and weeks 2, 6, and 12. Subgroup analysis evaluated average IOP change from baseline in tx‐naïve vs previously treated, washed out patients. Results FCBT PF was equivalent to Ganfort, producing numerically greater (0.2 to 0.5 mmHg) IOP lowering than Ganfort during follow‐up. With FCBT PF, IOP mean changes from baseline (mmHg) ranged from −8.7 to –9.8 in tx‐naïve patients (n=50) and –7.3 to –8.5 in previously treated patients (n=228). Baseline IOP, age, diagnosis, and corneal pachymetry were significant covariates of IOP lowering. In an analysis of covariance model with these factors as covariates, differences between tx‐naïve and previously treated patients ranged from 0.8 to 1.7 mm Hg favouring tx‐naive patients and were significant (p≤0.018) at 7 of 9 timepoints. Conclusion FCBT PF had a favourable IOP‐lowering effect compared with Ganfort and reduced IOP more effectively in tx‐naïve than previously treated patients. This can be attributed in part to the removal of preservative (BAK) optimizing the efficacy of timolol in FCBT PF. Commercial interest